ERBB2 and breast carcinoma: Consistent with this finding, a study with 1270 female patients with breast cancer showed that PIK3CA mutations are more prevalent in hormone receptor-positive breast cancer, especially with HER2-negative status (31.4%) in comparison to TNBC (11.7%) [135].